Discovery of protein biomarkers for renal diseases

Journal of the American Society of Nephrology

Volumn 15, Issue 7, 2004, Pages 1677-1689

  Hewitt, Stephen M ^a   Dear, James ^b   Star, Robert A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ALPHA 1 MICROGLOBULIN; BIOLOGICAL MARKER; CYSTATIN C; CYSTEINE RICH PROTEIN 61; FUMARYLACETOACETASE; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; KIM 1 PROTEIN; LIPOCALIN; PROTEIN; PROTEIN S100B; SODIUM PROTON EXCHANGE PROTEIN 3; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; CLINICAL RESEARCH; EARLY DIAGNOSIS; GENOMICS; HUMAN; KIDNEY DISEASE; LABORATORY TEST; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SCREENING; SYSTEMATIC REVIEW; TECHNOLOGY;

EID: 3042570252     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000129114.92265.32     Document Type: Review

References (75)

1. Sung NS, Crowley WF Jr, Genel M, Salber P, Sandy L, Sherwood LM, Johnson SB, Catanese V, Tilson H, Getz K, Larson EL, Scheinberg D, Reece EA, Slavkin H, Dobs A, Grebb J, Martinez RA, Korn A, Rimoin D: Central challenges facing the national clinical research enterprise. JAMA 289: 1278-1287, 2003
2. Tomlanovich S, Golbetz H, Perlroth M, Stinson E, Myers BD: Limitations of creatinine in quantifying the severity of cyclosporine-induced chronic nephropathy. Am J Kidney Dis 8: 332-337, 1986
3. Baboolal K, Jones GA, Janezic A, Griffiths DR, Jurewicz WA: Molecular and structural consequences of early renal allograft injury. Kidney Int 61: 686-696, 2002
4. Star RA: Treatment of acute renal failure. Kidney Int 54: 1817-1831, 1998
5. Miyaji T, Hu X, Yuen PS, Muramatsu Y, Iyer S, Hewitt SM, Star RA: Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int 64: 1620-1631, 2003
6. Frank R, Hargreaves R: Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2: 566-580, 2003
7. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y: Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93: 1054-1061, 2001
8. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L: The case for early detection. Nat Rev Cancer 3: 243-252, 2003
9. De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, Gail MH, Prentice R, Wittes J, Zeger SL: Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. Control Clin Trials 22: 485-502, 2001
10. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89-95, 2001
11. Bandara LR, Kelly MD, Lock EA, Kennedy S: A potential biomarker of kidney damage identified by proteomics: Preliminary findings. Biomarkers 8: 272-286, 2003
12. Ferber G: Biomarkers and proof of concept. Methods Find Exp Clin Pharmacol 24[Suppl C]: 35-40, 2002
13. Henney J: A regulatory agency's perspective on the application of biomarkers and surrogate end points in clinical trials. In: Biomarkers and Surrogate Endpoints, edited by Downing GJ, New York, Elsevier Science, 2000, pp xiv-xviii
14. Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, Balk E, Lau J, Levin A, Kausz AT, Eknoyan G, Levey AS: National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: Evaluation, classification, and stratification. Pediatrics 111: 1416-1421, 2003
15. Mehta RL, Chertow GM: Acute renal failure definitions and classification: Time for change? J Am Soc Nephrol 14: 2178-2187, 2003
16. Ronco C, Kellum JA, Mehta R: Acute dialysis quality initiative (ADQI). Nephrol Dial Transplant 16: 1555-1558, 2001
17. Kudva YC, Sawka AM, Young WF Jr: Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: The Mayo Clinic experience. J Clin Endocrinol Metab 88: 4533-4539, 2003
18. du CD, Daubin C, Poggioli J, Ramakers M, Houillier P, Charbonneau P, Paillard M: Urinary measurement of Na+/H+ exchanger isoform 3 (NHE3) protein as new marker of tubule injury in critically ill patients with ARF. Am J Kidney Dis 42: 497-506, 2003
19. Dadhania D, Muthukumar T, Ding R, Li B, Hartono C, Serur D, Seshan SV, Sharma VK, Kapur S, Suthanthiran M: Molecular signatures of urinary cells distinguish acute rejection of renal allografts from urinary tract infection. Transplantation 75: 1752-1754, 2003
20. Li B, Hartono C, Ding R, Sharma VK, Ramaswamy R, Qian B, Serur D, Mouradian J, Schwartz JE, Suthanthiran M: Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 344: 947-954, 2001
21. Vogelmann SU, Nelson WJ, Myers BD, Lemley KV: Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 285: F40-F48, 2003
22. Suto T, Losonczy G, Qiu C, Hill C, Samsell L, Ruby J, Charon N, Venuto R, Baylis C: Acute changes in urinary excretion of nitrite + nitrate do not necessarily predict renal vascular NO production. Kidney Int 48: 1272-1277, 1995
23. Dos Remedios CG, Liew CC, Allen PD, Winslow RL, Van Eyk JE, Dunn MJ: Genomics, proteomics and bioinformatics of human heart failure. J Muscle Res Cell Motil 24: 251-260, 2003
24. Mehta AI, Ross S, Lowenthal MS, Fusaro V, Fishman DA, Petricoin EF III, Liotta LA: Biomarker amplification by serum carrier protein binding. Dis Markers 19: 1-10, 2003
25. Liotta LA, Ferrari M, Petricoin E: Clinical proteomics: Written in blood. Nature 425: 905, 2003
26. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577, 2002
27. Baggerly KA, Morris JS, Coombes KR: Reproducibility of SELDI-TOF protein patterns in serum: Comparing data sets from different experiments. Bioinformatics 20: 777-785, 2004
28. Diamandis EP: Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: Opportunities and potential limitations. Mol Cell Proteomics 3: 367-378, 2004
29. Diamandis EP: Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems. J Natl Cancer Inst 96: 353-356, 2004
30. Yasui Y, Pepe M, Thompson ML, Adam BL, Wright GL Jr, Qu Y, Potter JD, Winget M, Thornquist M, Feng Z: A data-analytic strategy for protein biomarker discovery: Profiling of high-dimensional proteomic data for cancer detection. Biostatistics 4: 449-463, 2003
31. Riedemann NC, Guo RF, Ward PA: The enigma of sepsis. J Clin Invest 112: 460-467, 2003
32. Muramatsu Y, Tsujie M, Kohda Y, Pham B, Perantoni AO, Zhao H, Jo SK, Yuen PS, Craig L, Hu X, Star RA: Early detection of cysteine rich protein 61 (CYR61, CCN1) in urine following renal ischemic reperfusion injury. Kidney Int 62: 1601-1610, 2002
33. Devarajan P, Mishra J, Supavekin S, Patterson LT, Steven PS: Gene expression in early ischemic renal injury: Clues towards pathogenesis, biomarker discovery, and novel therapeutics. Mol Genet Metab 80: 365-376, 2003
34. Anderson L, Seilhamer J: A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18: 533-537, 1997
35. Gygi SP, Rochon Y, Franza BR, Aebersold R: Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19: 1720-1730, 1999
36. Brooks HL, Ageloff S, Kwon TH, Brandt W, Terris JM, Seth A, Michea L, Nielsen S, Fenton R, Knepper MA: cDNA array identification of genes regulated in rat renal medulla in response to vasopressin infusion. Am J Physiol Renal Physiol 284: F218-F228, 2003
37. Knepper MA: Proteomics and the kidney. J Am Soc Nephrol 13: 1398-1408, 2002
38. Van Balkom BW, Hoffert JD, Chou CL, Knepper MA: Proteomic analysis of long-term vasopressin action in the inner medullary collecting duct of the Brattleboro rat. Am J Physiol Renal Physiol 286: F216-F224, 2004
39. Kennedy S: The role of proteomics in toxicology: Identification of biomarkers of toxicity by protein expression analysis. Biomarkers 7: 269-290, 2002
40. Kohda Y, Murakami H, Moe OW, Star RA: Analysis of segmental renal gene expression by laser capture microdissection. Kidney Int 57: 321-331, 2000
41. Murakami H, Liotta L, Star RA: IF-LCM: Laser capture microdissection of immunofluorescently defined cells for mRNA analysis rapid communication. Kidney Int 58: 1346-1353, 2000
42. Simone NL, Remaley AT, Charboneau L, Petricoin EF III, Glickman JW, Emmert-Buck MR, Fleisher TA, Liotta LA: Sensitive immunoassay of tissue cell proteins procured by laser capture microdissection. Am J Pathol 156: 445-452, 2000
43. Knepper MA: Proteomics and the kidney. J Am Soc Nephrol 13: 1398-1408, 2002
44. Srinivas PR, Verma M, Zhao Y, Srivastava S: Proteomics for cancer biomarker discovery. Clin Chem 48: 1160-1169, 2002
45. Arthur JM: Proteomics. Curr Opin Nephrol Hypertens 12: 423-430, 2003
46. Thongboonkerd V, Klein E, Klein JB: Sample preparation for 2-D proteomic analysis. Contrib Nephrol 141: 11-24, 2004
47. Diehn M, Eisen MB, Botstein D, Brown PO: Large-scale identification of secreted and membrane-associated gene products using DNA microarrays. Nat Genet 25: 58-62, 2000
48. Lal A, Lash AE, Altschul SF, Velculescu V, Zhang L, McLendon RE, Marra MA, Prange C, Morin PJ, Polyak K, Papadopoulos N, Vogelstein B, Kinzler KW, Strausberg RL, Riggins GJ: A public database for gene expression in human cancers. Cancer Res 59: 5403-5407, 1999
49. Nishizuka S, Chen ST, Gwadry FG, Alexander J, Major SM, Scherf U, Reinhold WC, Waltham M, Charboneau L, Young L, Bussey KJ, Kim S, Lababidi S, Lee JK, Pittaluga S, Scudiero DA, Sausville EA, Munson PJ, Petricoin EF, III, Liotta LA, Hewitt SM, Raffeld M, Weinstein JN: Diagnostic markers that distinguish colon and ovarian adenocarcinomas: Identification by genomic, proteomic, and tissue array profiling. Cancer Res 63: 5243-5250, 2003
50. Park KM, Byun JY, Kramers C, Kim JI, Huang PL, Bonventre JV: Inducible nitric-oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney. J Biol Chem 278: 27256-27266, 2003
51. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847, 1998
52. Hewitt SM: Design, construction, and use of tissue microarrays. Methods Mol Biol 278: 61-72, 2004
53. Oda H, Shiina Y, Seiki K, Sato N, Eguchi N, Urade Y: Development and evaluation of a practical ELISA for human urinary lipocalin-type prostaglandin D synthase. Clin Chem 48: 1445-1453, 2002
54. Star R, Hostetter T, Hortin GL: New markers for kidney disease. Clin Chem 48: 1375-1376, 2002
55. Aleman M, Karakiewicz PI, Kupelian P, Kattan MW, Graefen M, Cagiannos I, Eastham J, Scardino PT, Huland H, Klein EA: Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: Implications for screening. Urology 62: 70-74, 2003
56. Morrow DA, Braunwald E: Future of biomarkers in acute coronary syndromes: Moving toward a multimarker strategy. Circulation 108: 250-252, 2003
57. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P: Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14: 2534-2543, 2003
58. Zheng Y, Xu Y, Ye B, Lei J, Weinstein MH, O'Leary MP, Richie JP, Mok SC, Liu BC: Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 98: 2576-2582, 2003
59. Rosenblatt KP, Bryant-Greenwood P, Killian JK, Mehta A, Geho D, Espina V, Petricoin EF, Liotta LA: Serum proteomics in cancer diagnosis and management. Annu Rev Med 55: 97-112, 2004
60. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R: Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 17: 994-999, 1999
61. Templin MF, Stoll D, Schwenk JM, Potz O, Kramer S, Joos TO: Protein microarrays: Promising tools for proteomic research. Proteomics 3: 2155-2166, 2003
62. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin III EF, Liotta LA: Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20: 1981-1989, 2001
63. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, Kouros-Mehr H, Bussey KJ, Lee JK, Espina V, Munson PJ, Petricoin E III, Liotta LA, Weinstein JN: Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sc. U S A 100: 14229-14234, 2003
64. Miyaji T, Hewitt SM, Liotta LA, Star RA: Frozen protein arrays: a new method for arraying and detecting recombinant and native tissue proteins. Proteomics 2: 1489-1493, 2002
65. Imyanitov EN, Togo AV, Hanson KP: Searching for cancer-associated gene polymorphisms: Promises and obstacles. Cancer Lett 204: 3-14, 2004
66. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV: Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 62: 237-244, 2002
67. Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV: Kidney injury molecule-1: A tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 286: F552-F563, 2004
68. Kwon O, Molitoris BA, Pescovitz M, Kelly KJ: Urinary actin, interleukin-6, and interleukin-8 may predict sustained ARF after ischemic injury in renal allografts. Am J Kidney Dis 41: 1074-1087, 2003
69. Usuda K, Kono K, Dote T, Nishiura K, Miyata K, Nishiura H, Shimahara M, Sugimoto K: Urinary biomarkers monitoring for experimental fluoride nephrotoxicity. Arch Toxicol 72: 104-109, 1998
70. Herget-Rosenthal S, Poppen D, Husing J, Marggraf G, Pietruck F, Jakob HG, Philipp T, Kribben A: Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem 50: 552-558, 2004
71. Melnikov VY, Ecder T, Fantuzzi G, Siegmund B, Lucia MS, Dinarello CA, Schrier RW, Edelstein CL: Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest 107: 1145-1152, 2001
72. Schaub S, Rush D, Wilkins J, Gibson IW, Weiler T, Sangster K, Nicolle L, Karpinski M, Jeffery J, Nickerson P: Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 15: 219-227, 2004
73. Herget-Rosenthal S, Marggraf G, Goring F, Philipp T, Kribben A: Serum cystatin C permits early detection of acute renal failure [Abstract]. J Am Soc Nephrol 14: 44A, 2003
74. Iglesias J, Marik PE, Levine JS: Elevated serum levels of the type I and type II receptors for tumor necrosis factor-alpha as predictive factors for ARF in patients with septic shock. Am J Kidney Dis 41: 62-75, 2003
75. Pelinka LE, Harada N, Szalay L, Jafarmadar M, Redl H, Bahrami S: Release of S100B differs during ischemia and reperfusion of the liver, the gut, and the kidney in rats. Shock 21: 72-76, 2004